for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TAKARA BIO INC.

4974.T

Latest Trade

2,072.00JPY

Change

12.00(+0.58%)

Volume

271,800

Today's Range

2,061.00

 - 

2,091.00

52 Week Range

1,943.00

 - 

2,829.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,060.00
Open
2,061.00
Volume
271,800
3M AVG Volume
8.24
Today's High
2,091.00
Today's Low
2,061.00
52 Week High
2,829.00
52 Week Low
1,943.00
Shares Out (MIL)
120.42
Market Cap (MIL)
248,056.10
Forward P/E
56.15
Dividend (Yield %)
0.34

Next Event

Q3 2020 Takara Bio Inc Earnings Release

Latest Developments

More

Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan

Takara Holdings' subsidiary Takara Bio says merger between US-based units

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TAKARA BIO INC.

TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.

Industry

Biotechnology & Drugs

Contact Info

7-4-38, Noji-Higashi

+81.77.5656920

http://www.takara-bio.co.jp

Executive Leadership

Hisashi Ohmiya

Chairman of the Board

Koichi Nakao

President, Executive President, President of Subsidiary, Representative Director

Masaharu Watabe

Managing Executive Officer, Director of Finance

Shuichiro Matsuzaki

Vice President, Executive Vice President, Director

Junichi Mineno

Managing Director, Managing Executive Officer, Chief Director of Bio-Industry Support Business Division, Manager of CDM Center

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

11.240

2018

19.390

2019

30.380

2020(E)

36.688
Price To Earnings (TTM)
61.83
Price To Sales (TTM)
7.10
Price To Book (MRQ)
3.85
Price To Cash Flow (TTM)
34.22
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
6.25
Return on Equity (TTM)
5.79

Latest News

Latest News

BRIEF-Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan

* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26

BRIEF-Takara Bio starts first test of Phase II clinical trial of HF10

* Says it started first test of Phase II clinical trial of HF10, which will be used for treatment in patients with unresectable or metastatic melanoma, on May 26

BRIEF-Takara Holdings' subsidiary Takara Bio says merger between US-based units

* Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen...

BRIEF-Takara Bio to start phase I/II clinical trials of gene therapy for sarcoma treatment

* Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma

BRIEF-Takara Bio's unit completes acquisition of Rubicon Genomics

* Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up